

Original Research

AN OVERVIEW OF THE SYNERGISTIC INFLUENCES BETWEEN ASTHMA AND TYPE-II DIABETES MELLITUS

Nawal Othman Alaawar^{1*}, Najia Albashir Mahdawi², Ibrahim Bashir Abdurrahman Karim³

^{1*}Family Medicine specialist, Al Rayyan HC, Doha, Qatar, nalaawar@phcc.gov.qa

² Medicine Department, Faculty of Medicine, Gharyian University, Libya, Najia.mahdawi@gu.edu.ly

³Head of medical department, Central Gharian Hospital/ Faculty of medicine, Ibrahim2062@yahoo.com

Abstract

This research aims to examine existing research on the relationship among (T2DM) type 2 diabetes mellitus and asthma in adulthood, the processes underlying this relationship, and the effects of T2DM on asthma management. It has been hypothesized that moderate levels of systemic inflammation or the application of antibiotics are to blame for the link between T2DM and asthma. It is noted that till now, there has been little scholarly research on the effects of this link on asthma management. The epidemiological statistics and routine healthcare procedures show that people with asthma also frequently have different kinds of diabetes mellitus (DM). The debate over the effects of an inflammatory disorder associated with asthma on glucose metabolism and the prevalence of persistent hyperglycemia and signs of inflammation in asthma patients remains debatable. It has been demonstrated that dysfunctional immune systems and genetic predisposition are related to asthma and type 1 diabetes mellitus (T1DM) and that obesity and insulin resistance (IR) plays a crucial role in promoting an excessively inflammatory nature and immune system reactions in type 2 diabetes mellitus. According to the findings, DM and asthma either impact one another's clinical manifestations, prognosis factors, and treatment options. Regardless of the probable involvement of metformin and the hyperglycemic adverse reactions to glucocorticoids, there is continuing debate regarding the efficacy and safety of anti-asthma and hypoglycemic treatment in this population of participants. Conclusion: Asthma and type 2 diabetes (T2DM) are two prevalent chronic diseases with a rising incidence that frequently interact in the same individual. It has been hypothesized that this cohabitation makes asthma management more severe. Since T2DM is a comorbidity linked with asthma, the research could promote legislative initiatives and therapeutic medical procedures that value this strategy with the objective to decrease the standard of life and other dangers to health. Consequently, the goal of the article being given is to examine what is known about the correlation between DM and asthma, their likely relationships with each other, and treatment possibilities.

Keywords: Type 2 Diabetes mellitus, Asthma, Immunology studies

INTRODUCTION

Individuals with diabetes mellitus (DM) and asthma are common in everyday healthcare settings, whether pneumological or diabetic. The connection among these illnesses is important from either a systematic or treatment point of view because of the pathogenic and treatment variety of the kinds of DM and the asthma medicines used by those suffering from it [1]. The various factors associated between asthma and Type 2 diabetes mellitus are described in the schema below in Figure 1.




Figure 1. Schematic overview of factors associated between Type 2 diabetes and asthma, reproduced with permission from [2]

According to the perspective of theory, it is important to look for the variables affecting the common progression of the two illnesses and potential etiological processes underlying their cohabitation. According to a practical standpoint, acquiring this type of data may enable the creation of diagnostic strategies for DM in asthma patients, the identification of the shared clinical image, and determining the suitable treatment regimes in conjunction with cases. The effect of inflammatory indicators connected to asthma on glucose metabolism is still being debated, despite research examining the etiopathological connection between DM and asthma. On the contrary conjunction, the information at hand indicates a substantial impact of the decomposition of carbohydrates on the prevalence of discomfort in the physique of the patient. These worries are caused by the dearth of investigations examining the connection between asthma and the onset of DM. Functional asthma is a diverse illness defined by persistent inflammation and hyperresponsiveness of the airways. The multifactorial illness known as type 2 diabetes mellitus (T2DM) is primarily defined by a decline in sensitivity to insulin as well as by a deficiency in the secretion of insulin and chronic inflammation.

Although it has been suggested that asthma is a major pulmonary disease, investigations have shown that it is also linked to extrapulmonary complications like obstructive sleep apnea syndrome (OSAS) and chronic conditions like overweight, type 2 diabetes (DM), and metabolic disorder. (SM). Obesity, T2DM, and asthma are three very prevalent chronic health problems. According to current

figures, there are 340 million asthmatics, 465 million people with diabetes, and 649 million obese people in the globe. According to statistics, there are 19% of people in Brazil are obese, 9 % have diabetes, and 6% have asthma, creating a significant fiscal load due to morbidity and mortality. Because of the modernization of living, those chronic diseases are becoming more common in developing nations at an alarming rate. Though the process of tying these three chronic diseases together is not well known, obesity appears to be a significant factor in the association between T2DM and asthma. Obesity and asthma may combine effectively, raising bloodstream amounts of cytokines that are inflammatory and raising the chance of insulin intolerance and type 2 diabetes (T2DM) [3].

Nevertheless, independent of body mass index (BMI), asthma has been scientifically linked to a higher incidence of T2DM in females, suggesting that chronic inflammation plays a major role in the development of diabetes. Additional investigation is required to determine the function of being overweight in the pathogenic mechanisms that connect T2DM and asthma. Conditions play an important role in the treatment and outlook of asthma because they are connected to common control of the disease, increased use of medical services, and decreased standard of living. In the view of investigations, comorbid conditions like T2DM may be more prevalent in asthmatics than in subjects with no condition. They may lead to a worse results, higher use of medical resources, and a lower standard of lifestyle [4]. Although some theories have been proposed, the potential processes underlying the link between asthma and chronic illnesses still need to be fully understood. New studies indicate that several variables could contribute to this relationship, including low-grade systemic inflammation, genetic pluralism, chronic oxidative stress, and medication use. The design is crucial to remember that the asthma pattern can change or exacerbate the different possible pathways for the greater likelihood of T2DM among people with asthma. This research seeks to evaluate the scientific literature on the relationship between the airway and T2DM, the processes underlying this link, and its effects on asthma management while considering these factors. The establishment of government regulations and medical procedures that ensure improved treatment for people with residing persistent illnesses like asthma and T2DM, striving for an integrated strategy at all medical care quantities for such individuals, in addition to higher expected life outcomes and lower expenses may be facilitated by this theme [5].

Epidemiological Research

A significant health issue presently is DM and its consequences. Data indicate that by 2045, there will be 629 million adult patients with DM, up from the projected 425 million patients in 2016 who are patients aged 20 to 80. It should be mentioned that type 2 (T2DM) diabetes, which affects 80-90% of diabetic patients, is the most prevalent form in adults. Individuals with type 1 diabetes mellitus, also known as T1DM, and 1-2% of women who have been identified with the disease, as well as people who have other diabetes brought on by mutations in genes, additional long-term illnesses (especially pancreatic diseases), or medicines taken, make up the remaining population [6]. The ratios are inverted in kids and teens, where T1DM predominates, and there are over one million individuals presently. Notably, the prevalence of T2DM is steadily rising in this age group as a result of the global epidemic of obesity. Particularly, mature males are significantly more likely than women to develop DM. The incidence of this illness was 9.1% for men and 8% for women in 2015; projections indicate that by 2026, these rates will rise to 13% for men and 11% for women [7]. The statistics show that dyspnea has a marginally lower prevalence than diabetes mellitus. Around 335

million people worldwide had the illness identified in 2013, and there were notable variations among the evaluated nations. Asthma instances are thought to be steady, in opposition to diabetes mellitus (DM), with a rapid increase in emerging nations and a decline in prevalence in established nations. It should be mentioned that while weight gain and smoking are two of the foremost risk factors for getting the illness, masculine infants are more likely to experience symptoms from breathlessness. Bronchitis and different kinds of DM coexist, according to many studies [8]. Patients with asthma are more likely to experience DM, according to a meta-analysis of 12 clinical trials done on a cohort of more than 500 000 patients aged 50-12 years with and without the condition. The prevalence of breathlessness and/or COPD was linked to a 2-fold higher incidence of T2DM in the age- and standardized treatment-adjusted group compared to individuals in good health. It must be noted that the likelihood of developing diabetes was irrespective of having any of the typical diabetogenic risk factors, such as lack of exercise, tobacco use, using hormone replacement therapies, drinking too much alcohol, having relatives with a history of DM and elevated blood pressure, having high familial cholesterol, and having an improper diet [9]. According to an investigation conducted by Finnish investigators, having been diagnosed with asthma raised the risk of developing type 1 diabetes (T1DM) by 40%, while having previously been diagnosed with T1DM reduced the chance of developing asthma by 20%. It is important to note that these outcomes were unaffected by the pertinent hazards, such as age at evaluation, birth ten years, sexuality, maternal asthma or diabetes, or childbirth-related variables. Chinese researchers made a comparable discovery in a group of grownups. DM was identified as one of the main illnesses combined with wheezing and arterial hypertension, cardiac arrest, and stroke caused by ischemia.

Additionally, empirical research showed an important link between the chance of developing asthma and factors related to lifestyle that influence the absorption of carbohydrates, including a person's body mass index (BMI), tobacco use, consuming alcohol, educational attainment, and internet and television use. According to observational research using the Austro-German DPV database structure, 4% of T1DM patients under 21 also had asthmatic or were being treated for it. Individuals with asthma were more likely to be men, older, and to have had diabetes for an extended period of time [10].

Immuno-pathology Studies

A persistent inflammatory condition called asthma is a variety of illnesses that results in a change in the airways. Dendritic cells and Th2 cells, which produce, among other things, IL-4, IL-5, GSDMB, and ORMDL3, play a significant role in the etiopathogenesis of asthma. These cells ensure the correct functioning of epithelial obstacles, intrinsic and acquired immune system responses, and other genetics. They are all crucial for the development and survival of eosinophils, their attraction to the pulmonary mucous membrane, the antigen flipping of B-cells, and the production of immunoglobulin E, or immunoglobulin (IgE), which, as attached to the right receptors, triggers the mast cells. Different hereditary and environmental factors combine to cause a slow loss of pancreas cell mass and/or its normal function [11]. Although the development of multiple types of diabetes is almost less complicated than this, it still contains these factors. By influencing the attachment of HLA protein with carrier peptides and the presentation of antigens to T cells, the different versions of chromosomes in one major locus—human leukocyte antigen (HLA)—are linked to a 55–65% rise in the genetic risk for DM in the case of T1DM. It is important to note that these cannot be the only traits contributing to the onset of this illness. There may be around 50 of these genes, and everyone

plays a role in modulating the immune system's control, among other things. It's important to stress the potential connection between outside influences like diseases (primarily viral), foods (gluten), the development of autoimmune disorders, and the likelihood of developing T1DM. In this case, the prevalence of autoimmunity represents the T and B cells' fundamental immune reaction to the cell pathogens [12].

The two primary causes of T2DM are obesity and resistance to insulin (IR). In recent years, researchers have discovered a strong link between having too much body fat and how well the immune system works. It has been shown that this mechanism significantly affects, among other things, the development of fatty tissue and the avoidance of ectopic lipid accumulation. The malfunctioning adipose cells (caused by caloric overflow) are defined by a number of abnormalities, such as abundant leptin secretion and decreased adiponectin manufacturing, hypoxia, and abundant cellular framework — collagen and elastic — accumulation. As a result of these alterations, the immune system may be activated and/or stimulated, resulting in an overabundance of immune cell types that continue to produce toxic cytokines. However, the research found no correlation between the prevalence of dyspnea during workouts and peak respiration rate, peak breathing equivalent of carbon dioxide (CO₂), or cytokines that promote inflammation like IL-6 and IL-1 in the blood. Some researchers distinguish between two characteristics of obese asthmatic patients: early atopic Th2-high type breathing problems with worsening bronchial inflammation and higher concentrations of IgE, in which asthma is exacerbated by weight gain, and late, non-atopic Th2-low type asthma, which primarily affects women and develops as a result of obesity and corresponds to a lower incidence of atopy, the bronchial hypersensitivity, airway obstruction, and a higher rate of exacerbation. The connection among fat, intestinal microbiota, and immune-mediated illnesses like asthma is gaining popularity [13].

This mechanism also appears to be unresolved, but there are signs that, in addition to IgA and calprotectin generated from the mucous membranes upon interaction with lipopolysaccharides (LPS), production of short-chain fatty acids (SCFA), bile acids that are produced, and other compounds of the intestinal microflora is also likely required. According to an animal paradigm used in research, the rodents given a meal rich in fat and low in carbs (70% fat, 30% protein content, and 2% carbohydrates) had greater LPS quantities [14].

A diet such as this was found to significantly alter not only the intestinal flora by a substantial decrease in the total number of both Gram-positive and Gram-negative microbes (*Lacto-bacillus* spp., *Bifidobacterium* spp., and *Bacteroides-Prevotella* spp.) but also the permeation of the intestines due to a drop in the amount of expression of epithelial tight junction proteins like ZO-1 [15].

The above association was entirely eliminated by introducing a 4-week antibiotic therapy, which resulted in a marked decrease in indicators of inflammation in the group that was given a high-fat diet. Additionally, it has been demonstrated that the commonly used high-fat diet is linked to a rise in plasma glucose, which the administration of antibiotic treatment decreases. The carbohydrate-based diet-induced increase in insulin release, the IR indicator, weight growth, total calorie intake, and the visceral and subcutaneous fat tissue quantity are all related findings [16].

Clinical analysis

However, according to clinical statistics, DM constitutes one of the chronic illnesses most rarely found in people with asthma, whether their asthma is controlled or untreated. It has also been discovered that DM is marginally more common in fat and asthma patients with poorly managed respiratory system diseases. It is noteworthy that obesity is linked to worse symptoms, a breakdown and loss of grip on the course of the disease, a decline in quality of life, an alternative reaction to the medication used to treat the condition, the emergence of steroid resistance, and an absence of inflammation caused by eosinophils in individuals with asthma. Additionally, it has been demonstrated that similar to the situation with obesity, the diagnosis of IR is linked to a substantially higher likelihood of experiencing wheezing episodes and asthma-like symptoms. Additionally, it has been demonstrated that this association is unaffected by the gender of the patient and is stronger in cases of IR than fat. It is also important to note that weight can lead to loss of breath during exercise by lowering the respiratory residual volume's effective residual capacity. Adult obesity, especially in women, has been linked to asthma refractory to therapy and has a sputum composition that is more neutrophilic and less eosinophilic. The possibility of a link between diabetes mellitus (DM) and the risk of pneumococcal diseases, such as invasive pneumococcal disease (IPD) and community-acquired pneumonia (CAP), in adult individuals, particularly those under the age of 40 without associated conditions, should also be taken into consideration in daily clinical practice. It has been demonstrated that this chance rises with the length of DM and poor glycemic management. There were no palpable disparities in the frequency of asthma between the studied patient populations of those with and without diabetes in the Gene-Environment Interactions in Respiratory Diseases investigation, which included individuals with T2DM.

However, it was observed that individuals with DM reported dyspnea that limited walking speed slightly more frequently in the corresponding age categories. Compared to the general community, patients with DM aged 40-60 years remarked with greater frequency of chronic cough/presence of sputum. It has been recommended that those diagnosed with T1DM who have asthma, when juxtaposed with participants without allergies and asthma, are at a comparable age at DM diagnosis with a comparable incidence of overweight and obesity, diabetic ketoacidosis, as well as a comparable level of arterial blood pressure and lipid profiling. This is based on the before-cited review of the DPV database.

It was also demonstrated that individuals affected with T1DM and asthma use continuous subcutaneous insulin infusions more frequently and experience hypoglycemia coma more frequently. They must use much greater insulin doses and specific anti-asthma medications (60% of them are asthmatics, such as 30% who need inhaled glucocorticoids, 25% who use sympathomimetics, 7% who use leukocytes the receptor antagonists, and 4% who take other non-specific drugs). The individuals taking analogs had a higher HbA1c than patients taking IGCs and leukotriene modifiers [17].

Treatment

Both routine clinical procedures and academic findings point to an ongoing debate over the "carbohydrate" safeness of anti-asthma medicines and the choice of hypoglycemic medications for

individuals with asthmatic and DM. Glucocorticosteroids are the primary focus of the discussion on the safety of anti-asthma drugs in patients. According to a research study done by American researchers, individuals taking this class of medications regularly have a 5-fold increased chance of getting diabetes. Depending on the MarketScan data collection, It has been reported that considerable risk for the formation of T2DM was linked with most oral glucocorticosteroids (OGCs) thrice per year or more. Nevertheless, this danger was not observed among patients who took this class of medications less frequently, thrice times annually.

Additionally, several studies indicate a detrimental impact of omalizumab on the metabolic control of DM in individuals needing anti-IgE antibody medication and a favorable impact of mepolizumab. The form of DM has the biggest impact on the medication selection for asthma people. In T1DM, insulin delivered according to various therapeutic regimens is the preferred medication. According to research on a local population of 25 patients with more serious asthma attacks requiring OGCs and possibly beneath-the-skin or infusion pump treatment with insulin, hyperglycemia is linked to an increase in the amount of time the individuals must stay in the hospital for treatment [18].

It has been discovered that patients diagnosed with T1DM used medications for asthma at a substantially higher rate. Except for short-acting muscarinic antagonists, which were used more frequently in the T1DM patient group, they did not notice a statistically significant difference in administering the particular anti-asthma medicines among participants with and without DM. The apex of the occurrence was observed in the first year following the start of DM, and notably, the incidence of the use of anti-asthma medicines dropped over time. Because more hypoglycemic medications are becoming available, the circumstance is more complex for people with T2DM. The recommended medication for diabetics is metformin (MET), which should be administered to all patients capable of this medication and with no adverse reactions.

It is also important to note that neither the comparison group nor T1DM (8 per 1000 people per year) experienced increased asthma exacerbations after the first year. According to a retrospective, qualitative cohort study using American marketplace databases from 2010 to 2014 and patients with T2DM and allergies, the use of DPP4 antagonists like alogliptin, linagliptin, saxagliptin, this medication, or a combination of products that included these medications did not substantially impact risk-domain controlled asthma (RDAC), which is referred to as having not been hospitalized for asthma-related reasons, no infections of the lower respiratory system, and no asthma attacks [19].

Asthma and Type 2 Diabetes Mellitus

Reading the five papers included in this group's analysis revealed significant characteristics for the loss of asthma control when linked with T2DM, including glycemic changes, diagnostic of long-standing diabetes, diabetic microangiopathy, and inflammation. According to a prospective investigation, patients who have hyperglycemia from continuous therapy with corticosteroids have a harder time recovering from acute asthma attacks that necessitate being hospitalized and have longer hospital stays than those who do not. No matter the form of insulin treatment, the authors conclude that hyperglycemia is a factor that greatly lengthens the hospital stay for asthma exacerbation. Another study assessing diabetic patients and non-diabetic controls who received medical care for acute asthma worsening (70%) or COPD (30%) demonstrated that an exacerbation of prediagnosed diabetes invested thrice to long-term mortality among those with asthma concomitant obstructive

diseases than glycemic-changes during hospital treatment. The authors claim that having an earlier diagnosis of insulin resistance, but not having hyperglycemia throughout a recurrence of restrictive pulmonary illness has an effect on long-term immortality, but they do not specifically address the mechanisms implicated in the findings of this research. Establishing those results, a multicenter and observational study with cross-sectional analysis revealed that Hispanics/Latinos aged 20 to 80 years with respiratory disease (asthma, bronchitis, and COPD) and T2DM had mean values of increased forced expiratory volume in the first second (FEV₁), lower forced vital capacity (FVC), and higher mean-dyspnea evaluations than those without T2DM, regardless of age, sex, and smoking. Despite not much data demonstrating the immediate effects of T2DM on asthma control, studies show that people with metabolic problems such as corpulence and MS have poor control of this long-term condition. Researchers determine that intrinsic biological alterations in the lung related to diabetic microangiopathy cause respiratory manifestations and dysfunction, which could increase general morbidity and mortality from respiratory illnesses initially. Patients with serious asthma and class III obesity were more prone to have asthma that is uncontrolled than those with average BMI, according to the reports. According to another study comparing asthma control in people with and without MS, people with MS had worse symptom control than their counterparts without metabolic disease. In a trial with 430 obese and asthmatic MS patients, it was found that having MS raised the risk of losing management of wheezing during follow-up, adversely altering the impact of weight reduction on the maintenance of induced asthma for this therapy [20, 21].

Conclusion

According to epidemiological research, airway asthma and various kinds of diabetes are significantly correlated. Irrespective of the pathomechanism causing persistent hyperglycemia, it was recently discovered to be linked to the proinflammatory response's installation, which has a predominant relationship with the prevalence of wheezing and the intensity of the condition. Due to the relationship, every patient with an asthma diagnosis needs to have their diabetes evaluated as well. Due to the debate over the cause-and-effect connection between anti-asthma drugs and hyperglycemia, there are currently no hypoglycemic treatment guidelines for people with concurrent asthma and diabetes. Metformin continues to be the preferred medication in this situation, but new hypoglycemic medications like DPP4 antagonists have high expectations attached to them.

References

1. R.M. Torres, M.D.S. Souza, A.C.C. Coelho, L.M. de Mello, and C. Souza-Machado, "Association between asthma and type 2 diabetes mellitus: mechanisms and impact on asthma control-a literature review," *Can Respir J* 2021, 8830439 (2021).
2. P. Uppal, S.A. Mohammed, S. Rajashekar, S. Giri Ravindran, M. Kakarla, M. Ausaja Gambo, M. Yousri Salama, N. Haidar Ismail, P. Tavalla, and P. Hamid, "Type 2 Diabetes Mellitus and Asthma: Pathomechanisms of Their Association and Clinical Implications," *Cureus*, (2023).
3. A.E. Mirrakhimov, "Chronic obstructive pulmonary disease and glucose metabolism: a bittersweet symphony," *Cardiovasc Diabetol* 11(1), 132 (2012).
4. M. Bantulà, J. Roca-Ferrer, E. Arismendi, and C. Picado, "Asthma and Obesity: Two Diseases on the Rise and Bridged by Inflammation," *J Clin Med* 10(2), 169 (2021).

5. D. Visca, P. Pignatti, A. Spanevello, E. Lucini, and E. La Rocca, "Relationship between diabetes and respiratory diseases—Clinical and therapeutic aspects," *Pharmacological Research* 137, 230–235 (2018).
6. P. Saeedi, I. Petersohn, P. Salpea, B. Malanda, S. Karuranga, N. Unwin, S. Colagiuri, L. Guariguata, A.A. Motala, K. Ogurtsova, J.E. Shaw, D. Bright, and R. Williams, "Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition," *Diabetes Research and Clinical Practice* 157, 107843 (2019).
7. N.H. Cho, J.E. Shaw, S. Karuranga, Y. Huang, J.D. Da Rocha Fernandes, A.W. Ohlrogge, and B. Malanda, "IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045," *Diabetes Research and Clinical Practice* 138, 271–281 (2018).
8. M.H. Black, A. Anderson, R.A. Bell, D. Dabelea, C. Pihoker, S. Saydah, M. Seid, D.A. Standiford, B. Waitzfelder, S.M. Marcovina, and J.M. Lawrence, "Prevalence of Asthma and Its Association With Glycemic Control Among Youth With Diabetes," *Pediatrics* 128(4), e839–e847 (2011).
9. E. Forno, "Asthma and diabetes: Does treatment with metformin improve asthma?: Editorial," *Respirology* 21(7), 1144–1145 (2016).
10. A.C. Carlsson, P. Wändell, U. Ösby, R. Zarrinkoub, B. Wettermark, and G. Ljunggren, "High prevalence of diagnosis of diabetes, depression, anxiety, hypertension, asthma and COPD in the total population of Stockholm, Sweden – a challenge for public health," *BMC Public Health* 13(1), 670 (2013).
11. N. Habib, M.A. Pasha, and D.D. Tang, "Current Understanding of Asthma Pathogenesis and Biomarkers," *Cells* 11(17), 2764 (2022).
12. J. Krusche, S. Basse, and B. Schaub, "Role of early life immune regulation in asthma development," *Semin Immunopathol* 42(1), 29–42 (2020).
13. Y.T. Wondmkun, "Obesity, Insulin Resistance, and Type 2 Diabetes: Associations and Therapeutic Implications," *Diabetes Metab Syndr Obes* 13, 3611–3616 (2020).
14. P. Portincasa, L. Bonfrate, M. Vacca, M. De Angelis, I. Farella, E. Lanza, M. Khalil, D.Q.-H. Wang, M. Sperandio, and A. Di Ciaula, "Gut Microbiota and Short Chain Fatty Acids: Implications in Glucose Homeostasis," *IJMS* 23(3), 1105 (2022).
15. R. Ganesan, and K.T. Suk, "Therapeutic Potential of Human Microbiome-Based Short-Chain Fatty Acids and Bile Acids in Liver Disease," *Livers* 2(3), 139–145 (2022).
16. U. Peters, A.E. Dixon, and E. Forno, "Obesity and asthma," *J Allergy Clin Immunol* 141(4), 1169–1179 (2018).
17. L. Cipryan, P.B. Maffetone, D.J. Plews, and P.B. Laursen, "Effects of a four-week very low-carbohydrate high-fat diet on biomarkers of inflammation: Non-randomised parallel-group study," *Nutr Health* 26(1), 35–42 (2020).
18. R. Dineen, C.J. Thompson, and M. Sherlock, "Adrenal crisis: prevention and management in adult patients," *Ther Adv Endocrinol Metab* 10, 2042018819848218 (2019).
19. N. Scichilone, M.T. Ventura, M. Bonini, F. Braidò, C. Bucca, M. Caminati, S. Del Giacco, E. Heffler, C. Lombardi, A. Matucci, M. Milanese, R. Paganelli, G. Passalacqua, V. Patella, E. Ridolo, G. Rolla, O. Rossi, D. Schiavino, G. Senna, G. Steinhilber, A. Vultaggio, and G. Canonica, "Choosing wisely: practical considerations on treatment efficacy and safety of asthma in the elderly," *Clin Mol Allergy* 13(1), 7 (2015).

20. S.F. Ehrlich, C.P. Quesenberry, S.K. Van Den Eeden, J. Shan, and A. Ferrara, “Patients Diagnosed With Diabetes Are at Increased Risk for Asthma, Chronic Obstructive Pulmonary Disease, Pulmonary Fibrosis, and Pneumonia but Not Lung Cancer,” *Diabetes Care* 33(1), 55–60 (2010).
21. K. Gomułka, and M. Ruta, “The Role of Inflammation and Therapeutic Concepts in Diabetic Retinopathy—A Short Review,” *IJMS* 24(2), 1024 (2023)